GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » 14-Day RSI

Amicus Therapeutics (Amicus Therapeutics) 14-Day RSI : 33.84 (As of Apr. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-27), Amicus Therapeutics's 14-Day RSI is 33.84.

The industry rank for Amicus Therapeutics's 14-Day RSI or its related term are showing as below:

FOLD's 14-Day RSI is ranked better than
85.9% of 1575 companies
in the Biotechnology industry
Industry Median: 43.5 vs FOLD: 33.84

Competitive Comparison of Amicus Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Amicus Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amicus Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's 14-Day RSI falls into.



Amicus Therapeutics  (NAS:FOLD) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amicus Therapeutics  (NAS:FOLD) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Amicus Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Amicus Therapeutics (Amicus Therapeutics) Business Description

Traded in Other Exchanges
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Executives
John F Crowley director, officer: Executive Chairman C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark officer: Chief People Officer 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Samantha Prout officer: Principal Accounting Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradley L Campbell director, officer: President and CEO C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg officer: General Counsel & Corp. Secy C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Jeff Castelli officer: VP, Program Management 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r. officer: Chief Financial Officer AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab director 1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi officer: Chief Financial Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
Burke W Whitman director 13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts director C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do officer: Sr Vice President Discovery C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly director C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth officer: Chief Medical Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512